Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children.
OBJECTIVE
To determine total and functional serogroup C antibody response after vaccination with a quadrivalent meningococcal polysaccharide vaccine.


METHODS
Prospective, before and after intervention study.


METHODS
Study subjects were between the ages of 0.5 and 19.9 years, and were eligible for a community-wide public health immunization campaign against Neisseria meningitidis serogroup C.


METHODS
Total and functional antibody response was measured by enzyme-linked immunosorbent assay and bactericidal assay, respectively.


RESULTS
One month after vaccination, total capsular polysaccharide antibody significantly increased in all age groups; a significant rise in bactericidal antibody, that correlated with total capsular polysaccharide antibody, was seen in children 18 months of age and older. At 1 year bactericidal antibody titers were maintained but capsular polysaccharide antibody declined substantially in children younger than 5 years.


CONCLUSIONS
Total capsular polysaccharide antibody concentration appears to be a useful surrogate measure of bactericidal antibody in children 18 months and older. Children who originally received the vaccine at less than 18 months of age should be considered for revaccination if there is a new or continuing risk of disease. Because of the differences in the total and bactericidal antibodies formed, vaccine efficacy trials are required to define which serologic measures are associated with protection.
King
W J
WJ
Department of Pediatrics, Children's Hospital Eastern Ontario, University of Ottawa, Canada.
MacDonald
N E
NE
Wells
G
G
Huang
J
J
Allen
U
U
Chan
F
F
Ferris
W
W
Diaz-Mitoma
F
F
Ashton
F
F
D000293:Adolescent; D000328:Adult; D000917:Antibody Formation; D001428:Bacterial Vaccines / Q000276:immunology* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D016233:Immunotherapy, Active; D007223:Infant; D008297:Male; D008589:Meningococcal Infections / Q000276:immunology* / Q000517:prevention & control; D009345:Neisseria meningitidis / Q000276:immunology* / Q000302:isolation & purification; D011135:Polysaccharides, Bacterial / Q000276:immunology* / Q000627:therapeutic use; D011446:Prospective Studies; D014611:Vaccination
D001428:Bacterial Vaccines; D011135:Polysaccharides, Bacterial